» Articles » PMID: 28512154

Glucose Autoregulation is the Dominant Component of the Hormone-independent Counterregulatory Response to Hypoglycemia in the Conscious Dog

Abstract

The contribution of hormone-independent counterregulatory signals in defense of insulin-induced hypoglycemia was determined in adrenalectomized, overnight-fasted conscious dogs receiving hepatic portal vein insulin infusions at a rate 20-fold basal. Either euglycemia was maintained () or hypoglycemia (≈45 mg/dl) was allowed to occur. There were three hypoglycemic groups: one in which hepatic autoregulation against hypoglycemia occurred in the absence of sympathetic nervous system input (), one in which autoregulation occurred in the presence of norepinephrine (NE) signaling to fat and muscle (), and one in which autoregulation occurred in the presence of NE signaling to fat, muscle, and liver (). Average net hepatic glucose balance (NHGB) during the last hour for was -0.7 ± 0.1, 0.3 ± 0.1 ( < 0.01 vs. ), 0.7 ± 0.1 ( = 0.01 vs. ), and 0.8 ± 0.1 ( = 0.7 vs. ) mg·kg·min, respectively. Hypoglycemia per se () increased NHGB by causing an inhibition of net hepatic glycogen synthesis. NE signaling to fat and muscle () increased NHGB further by mobilizing gluconeogenic precursors resulting in a rise in gluconeogenesis. Lowering glucose per se decreased nonhepatic glucose uptake by 8.9 mg·kg·min, and the addition of increased neural efferent signaling to muscle and fat blocked glucose uptake further by 3.2 mg·kg·min The addition of increased neural efferent input to liver did not affect NHGB or nonhepatic glucose uptake significantly. In conclusion, even in the absence of increases in counterregulatory hormones, the body can defend itself against hypoglycemia using glucose autoregulation and increased neural efferent signaling, both of which stimulate hepatic glucose production and limit glucose utilization.

Citing Articles

Glucose as a Major Antioxidant: When, What for and Why It Fails?.

Cherkas A, Holota S, Mdzinarashvili T, Gabbianelli R, Zarkovic N Antioxidants (Basel). 2020; 9(2).

PMID: 32033390 PMC: 7070274. DOI: 10.3390/antiox9020140.


Pathophysiology and aetiology of hypoglycaemic crises.

Morgan R, Cortes Y, Murphy L J Small Anim Pract. 2018; 59(11):659-669.

PMID: 30102417 PMC: 7166581. DOI: 10.1111/jsap.12911.


Continuous Glucose Monitoring for Hypoglycemia Avoidance and Glucose Counterregulation in Long-Standing Type 1 Diabetes.

Rickels M, Peleckis A, Dalton-Bakes C, Naji J, Ran N, Nguyen H J Clin Endocrinol Metab. 2017; 103(1):105-114.

PMID: 29190340 PMC: 6283439. DOI: 10.1210/jc.2017-01516.

References
1.
Sacca L, Cryer P, Sherwin R . Blood glucose regulates the effects of insulin and counterregulatory hormones on glucose production in vivo. Diabetes. 1979; 28(6):533-6. DOI: 10.2337/diab.28.6.533. View

2.
Moghimzadeh E, Nobin A, ROSENGREN E . Fluorescence microscopical and chemical characterization of the adrenergic innervation in mammalian liver tissue. Cell Tissue Res. 1983; 230(3):605-13. DOI: 10.1007/BF00216204. View

3.
Huo L, Harding J, Peeters A, Shaw J, Magliano D . Life expectancy of type 1 diabetic patients during 1997-2010: a national Australian registry-based cohort study. Diabetologia. 2016; 59(6):1177-85. DOI: 10.1007/s00125-015-3857-4. View

4.
Chu C, Sindelar D, Igawa K, Sherck S, Neal D, Emshwiller M . The direct effects of catecholamines on hepatic glucose production occur via alpha(1)- and beta(2)-receptors in the dog. Am J Physiol Endocrinol Metab. 2000; 279(2):E463-73. DOI: 10.1152/ajpendo.2000.279.2.E463. View

5.
Cherrington A . Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes. 1999; 48(5):1198-214. DOI: 10.2337/diabetes.48.5.1198. View